Related Experiment Video
Updated: Jan 29, 2026

Pan-lyssavirus Real Time RT-PCR for Rabies Diagnosis
Published on: July 10, 2019
Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses
Venice Du Pont1, Richard K Plemper1, Matthias J Schnell2
1Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, United States.
Abstract:
Rabies virus (RABV) constitutes a major social and economic burden associated with 60 000 deaths annually worldwide. Although pre-exposure and post-exposure treatment options are available, they are efficacious only when initiated before the onset of clinical symptoms. Aggravating the problem, the current RABV vaccine does not cross-protect against the emerging zoonotic phylogroup II lyssaviruses. A requirement for an uninterrupted cold chain and high cost of the immunoglobulin component of rabies prophylaxis generate an unmet need for the development of RABV-specific antivirals. We discuss desirable anti-RABV drug profiles, past efforts to address the problem and inhibitor candidates identified, and examine how the rapidly expanding structural insight into RABV protein organization has illuminated novel druggable target candidates and paved the way to structure-aided drug optimization. Special emphasis is given to the viral RNA-dependent RNA polymerase complex as a promising target for direct-acting broad-spectrum RABV inhibitors.
Insights
Developing new rabies antivirals is crucial due to vaccine limitations and high costs. Targeting the RNA-dependent RNA polymerase offers a promising strategy for broad-spectrum rabies virus inhibitors.
Area of Science:
- Virology
- Drug Discovery
- Public Health
Background:
- Rabies virus (RABV) causes significant global mortality (60,000 deaths annually).
- Current vaccines are ineffective post-symptom onset and lack cross-protection against emerging lyssaviruses.
- Existing prophylaxis requires cold chains and expensive immunoglobulin, highlighting the need for novel antivirals.
Purpose of the Study:
- To review desirable anti-RABV drug profiles and past research efforts.
- To explore novel druggable targets for rabies virus based on structural insights.
- To emphasize the viral RNA-dependent RNA polymerase as a key target for direct-acting antivirals.
Main Methods:
- Literature review of anti-RABV drug development.
- Analysis of structural insights into RABV protein organization.
- Examination of inhibitor candidates and structure-aided drug optimization.
Main Results:
- Identification of novel druggable targets through advanced structural analysis.
- Evaluation of past inhibitor candidates and their limitations.
- Highlighting the viral RNA-dependent RNA polymerase complex as a prime target.
Conclusions:
- The development of RABV-specific antivirals is urgently needed.
- Structural biology provides new avenues for identifying and optimizing antiviral drugs.
- The RNA-dependent RNA polymerase complex presents a promising target for broad-spectrum rabies virus inhibitors.
Related Concept Videos
Emerging Adulthood
What are Viruses?
Introduction Cardiac Emergencies
Marcia's Theory of Identity Status
The Antiviral System of Bacteria and Archaea: CRISPR
Therapeutic Index

